Prostate cancer is the second most common cancer in men worldwide, and resistance to hormone therapies remains a significant challenge. Targeting PDIA1 and PDIA5 offers a novel strategy to overcome such resistance and improve patient outcomes, paving the way for more effective, combination treatment options in advanced prostate cancer management.
Prostate cancer cells rely on PDIA1 and PDIA5 as molecular bodyguards to maintain AR stability and resist treatment. When these enzymes were inhibited, the AR could not function properly and began breaking down. This not only led to cancer cell death but also made tumors more responsive to existing therapies like enzalutamide, a commonly prescribed AR-targeting drug.
Researchers from Flinders University, Australia, and South China University of Technology performed extensive experiments including patient-derived tumor samples and mouse models. Their findings showed impressive tumor shrinkage and enhanced treatment efficacy when PDIA1 and PDIA5 inhibitors were combined with enzalutamide.
Beyond AR protection, these enzymes help cancer cells manage stress and maintain energy production by supporting mitochondria, the cell’s powerhouses. Blocking PDIA1 and PDIA5 damages mitochondria, increases oxidative stress, and deprives cancer cells of energy—essentially cutting off both the “fuel” and “engine” that sustain tumor growth.
Lead researchers, including Professor Luke Selth and Dr. Jianling Xie, highlighted this dual impact as a promising therapeutic avenue. Although current inhibitors show potential, they require refinement to ensure safety and selectivity, as some may affect healthy cells.
REFERENCE: Jianling Xie, Kaikai Shen, Wenken Liang, Zijian Kuang, Raj K. Shrestha, Adrienne R. Hanson, Scott L. Townley, Meiling He, Sishu Yu, Peiwen Zhou, Liangzhen Zhu, Zhiwen Gong, Xiang Ao, Sushma R. Rao, Qing Zhang, Kaijie Chen, Jinfen Wei, Shashikanth Marri, Marten F. Snel, Swati Irani, Liye Chen, Ling Wang, Daniel P. McDougal, John B. Bruning, Minglin Ou, Shaobo Wang, Christopher G. Proud, Hongli Du, Lisa M. Butler, Luke A. Selth. Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival. Proceedings of the National Academy of Sciences, 2025; 122 (42) DOI: 10.1073/pnas.2509222122
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.